92
reverse transcriptase inhibitors, or both in the presence of nucleoside reverse transcriptase
inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
Lancet.2006 december 16; 368: 2125-35.
46. Klein MB, Willemot P, Murphy T, Lalonde RG.11l. The impact of initial highly active
antiretroviral therapy on future treatment sequences in HIV infection. AIDS. 2004; 18:
1895-1904.
47. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of
Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-
Drug Therapy. JAMA. 2001; 286(20):2568-77.
48. Leeuwen R, Katlama C, Murphy KS, Gatell J, Horban A, Bonaventura C, et al. A
randomized trial to study first line combination therapy with or without protease inibitor
in HIV-1 infected patients. AIDS.2003; 17(7): 987-99.
49. Sterling TR, Chaisson RE, Moore RD. HIV-RNA, CD4 T-lymphocytes, and clinical
response to highly active antiretroviral therapy. AIDS. 2001; 15: 2251-57.
50. Mathews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, et al.
Virological suppression at 6 months is related to choice of initial regimen in
antiretroviral-naïve patients: a cohort study. AIDS.2002; 16: 53-61.
51. Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chêne G. Clinical efficacy
of antiretroviral combination terapy based on protease inhibitors or non-nucleoside
analogue reverse transcriptase inhibitors: indirect comparation of controlled trials. BMJ.
2004 Jan 31; 328: 1-7
52. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al.
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection.
N Engl J Med. 2003; 349(24):2293-2303.
53. INITIO Trial International Co-ordinating Committee. Virological and immunological
outcomes at 3 years after starting antiretroviral therapy with regimens containing non-
nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-
label randomized trial. Lancet, v.368, p.287-298, 2006.
54. van Leth F ,Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al.
Comparison of first-line antiretroviral therapy with regimens including nevirapine,
efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the
2NN Study. Lancet 2004; 363: 1253–63
55. Bartlett JA, Fath MJ, DeMasi R, Hermes A, Quinn J, Mondou E, et al. An update
systematic overview of triple combination therapy in antiretroviral-naïve HIV-infected
adults. AIDS. 2006; 20: 2051-64.